as 05-17-2024 4:00pm EST
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | EMERYVILLE |
Market Cap: | 526.9M | IPO Year: | N/A |
Target Price: | $9.00 | AVG Volume (30 days): | 532.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.64 | EPS Growth: | N/A |
52 Week Low/High: | $3.82 - $6.71 | Next Earning Date: | 05-09-2024 |
Revenue: | $21,046,000 | Revenue Growth: | -68.29% |
Revenue Growth (this year): | -5.21% | Revenue Growth (next year): | 79.79% |
OABI Breaking Stock News: Dive into OABI Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Insider Monkey
8 days ago
Simply Wall St.
9 days ago
Simply Wall St.
9 days ago
Business Wire
10 days ago
Business Wire
19 days ago
Business Wire
a month ago
TipRanks
2 months ago